PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Back to Top
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase III | Treatment | Closed | 18 and over | Pharmaceutical / Industry | 9823 H6Q-MC-JCBJ, PRELUDE, NCT00332202 |
Summary
This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily.
This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of diffuse large B cell lymphoma
- Recently completed R-CHOP therapy and achieved remission
- IPI score 3,4,5
- At least 18 years of age
- Agree to study follow-up schedule
Exclusion Criteria:
- Have received therapy other than R-CHOP for lymphoma
- Serious medical condition such as infection,second cancer,heart disease
- Received radiation to more than one lesion
- Unable to swallow tablets
Trial Lead Organizations/Sponsors
Eli Lilly and Company
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) |  | Study Director |
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00332202
Information obtained from ClinicalTrials.gov on December 14, 2011
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
